

1 **TITLE**

2 Minimum Information about a Cardiac Electrophysiology Experiment (MICEE):
3 Standardised Reporting for Model Reproducibility, Interoperability, and Data Sharing

4 **AUTHOR NAMES**

5 Quinn TA^{1,2}, Granite S³, Alessie MA⁴, Antzelevitch C⁵, Bollensdorff C¹, Bub G⁶,
6 Burton RAB⁶, Cerbai E⁷, Chen PS⁸, Delmar M⁹, DiFrancesco D¹⁰, Earm YE¹¹, Efimov
7 IR¹², Egger M¹³, Entcheva E¹⁴, Fink M¹⁵, Fischmeister R¹⁶, Franz MR¹⁷, Garry A⁶,
8 Giles WR¹⁸, Hannes T¹, Harding SE¹, Hunter PJ^{6,19}, Iribe G²⁰, Jalife J²¹, Johnson
9 CR²², Kass RS²³, Kodama I²⁴, Koren G²⁵, Lord P²⁶, Markhasin VS²⁷, Matsuoka S²⁸,
10 McCulloch AD²⁹, Mirams GR², Morley GE⁹, Nattel S³⁰, Noble D^{2,6}, Olesen SP³¹,
11 Panfilov AV³², Trayanova NA^{3,33}, Ravens U³⁴, Richard S³⁵, Rosenbaum DS³⁶, Rudy
12 Y¹², Sachs F³⁷, Sachse FB³⁸, Saint DA³⁹, Schotten U⁴, Solovyova O²⁷, Taggart P⁴⁰,
13 Tung L³³, Varró A⁴¹, Volders PG⁴, Wang K^{1,2}, Weiss JN⁴², Wettwer E³⁴, White E⁴³,
14 Wilders R⁴⁴, Winslow RL^{3,33}, Kohl P^{1,2}

15 **AUTHOR AFFILIATIONS**

16 ¹National Heart and Lung Institute, Imperial College London, London, UK

17 ²Department of Computer Science, University of Oxford, Oxford, UK

18 ³Institute for Computational Medicine, Johns Hopkins University, Baltimore, USA

19 ⁴Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre,
20 Maastricht, The Netherlands

21 ⁵Masonic Medical Research Laboratory, Utica, USA

22 ⁶Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK

23 ⁷Center of Molecular Medicine (CIMMBA), University of Florence, Firenze, Italy

24 ⁸Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis,
25 USA

26 ⁹Department of Medicine, New York University School of Medicine, New York, USA

27 ¹⁰Department of Biomolecular Sciences and Biotechnology, University of Milan,
28 Milan, Italy

29 ¹¹Department of Physiology, Seoul National University College of Medicine, Seoul,
30 Korea

31 ¹²Department of Biomedical Engineering, Washington University, St. Louis, USA

32 ¹³Department of Physiology, University of Bern, Bern, Switzerland

33 ¹⁴Department of Biomedical Engineering, Stony Brook University, Stony Brook, USA

34 ¹⁵Modeling and Simulation, Novartis Pharma AG, Basel, Switzerland

35 ¹⁶Institut National de la Santé et de la Recherche Médicale, Université Paris-Sud,
36 Châtenay-Malabry, France

37 ¹⁷Veterans Affairs and Georgetown University Medical Center, Washington, USA

38 ¹⁸Faculty of Kinesiology, University of Calgary, Calgary, Canada

39 ¹⁹Auckland Bioengineering Institute, University of Auckland, Auckland, New Zealand

40 ²⁰Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama
41 University, Okayama, Japan

42 ²¹Department of Internal Medicine, University of Michigan, Ann Arbor, USA

43 ²²Scientific Computing and Imaging Institute, University of Utah, Salt Lake City, USA

44 ²³Department of Pharmacology, Columbia University, New York, USA

45 ²⁴Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan

46 ²⁵Division of Cardiology, Warren Alpert Medical School of Brown University,
47 Providence, USA

48 ²⁶School of Computing Science, Newcastle University, Newcastle-upon-Tyne, UK

49 ²⁷Institute of Immunology and Physiology, Ural Division of the Russian Academy of
50 Sciences, Yekaterinburg, Russia

51 ²⁸Center for Innovation in Immunoregulative Technology and Therapeutics, Kyoto
52 University, Kyoto, Japan

53 ²⁹Department of Bioengineering, University of California San Diego, La Jolla, USA

54 ³⁰Department of Medicine, Université de Montréal, Montreal, Canada

55 ³¹Department of Biomedical Sciences, University of Copenhagen, Copenhagen,
56 Denmark

57 ³²Department of Physics and Astronomy, Gent University, Gent, Belgium

58 ³³Department of Biomedical Engineering, Johns Hopkins University, Baltimore, USA

59 ³⁴Department of Pharmacology and Toxicology, Dresden University of Technology,
60 Dresden, Germany

61 ³⁵INSERM U1046, Université Montpellier1, Université Montpellier2, Montpellier,
62 France

63 ³⁶Heart and Vascular Research Center, Case Western Reserve University,
64 Cleveland, USA

65 ³⁷Department of Physiology and Biophysics, State University of New York at Buffalo,
66 Buffalo, USA

67 ³⁸Nora Eccles Harrison Cardiovascular Research and Training Institute, University of
68 Utah, Salt Lake City, USA

69 ³⁹School of Medical Sciences, University of Adelaide, Adelaide, Australia

70 ⁴⁰Department of Medicine, University College London, London, UK

71 ⁴¹Department of Pharmacology and Pharmacotherapy, University of Szeged,
72 Szeged, Hungary

73 ⁴²Department of Medicine, University of California at Los Angeles, Los Angeles, USA

74 ⁴³Multidisciplinary Cardiovascular Research Centre, University of Leeds, Leeds, UK

75 ⁴⁴Department of Anatomy, Embryology and Physiology, Academic Medical Center,
76 University of Amsterdam, Amsterdam, The Netherlands

77 **CORRESPONDING AUTHOR**

78 T Alexander Quinn, PhD

79 EPSRC Postdoctoral Research Fellow

80 National Heart and Lung Institute, Imperial College London

81 Heart Science Centre, Harefield, UB9 6JH, UK

82 Phone: 01865 272501

83 Fax: 01865 272554

84 t.quinn@imperial.ac.uk

85

86 ABSTRACT

87 Cardiac experimental electrophysiology is in need of a well-defined Minimum
88 Information Standard for recording, annotating, and reporting experimental data. As
89 a step toward establishing this, we present a draft standard, called *Minimum*
90 *Information about a Cardiac Electrophysiology Experiment* (MICEE). The ultimate
91 goal is to develop a useful tool for cardiac electrophysiologists which facilitates and
92 improves dissemination of the minimum information necessary for reproduction of
93 cardiac electrophysiology research, allowing for easier comparison and utilisation of
94 findings by others. It is hoped that this will enhance the integration of individual
95 results into experimental, computational, and conceptual models. In its present form,
96 this draft is intended for assessment and development by the research community.
97 We invite the reader to join this effort, and, if deemed productive, implement the
98 *Minimum Information about a Cardiac Electrophysiology Experiment* standard in their
99 own work.

100 KEY WORDS

101 Minimum Information Standard; Cardiac Electrophysiology; Data Sharing;
102 Reproducibility; Integration; Computational Modelling

103 ABBREVIATIONS

104 BioSignalML: BioSignal Markup Language
105 CellML: Cell Markup Language
106 DataStar: Data Staging Repository
107 dbGAP: Database of Genotypes and Phenotypes
108 DOI: Digital Object Identifier
109 FGED: Functional Genomics Data

- 110 GEO: Gene Expression Omnibus
- 111 MGED: Microarray Gene Expression Data
- 112 MIAME: Minimum Information About a Microarray Experiment
- 113 MIBBI: Minimum Information about a Biomedical or Biological Investigation
- 114 MICEE: Minimum Information about a Cardiac Electrophysiology Experiment
- 115 MINI: Minimum Information about a Neuroscience Investigation
- 116 SBML: Systems Biology Markup Language
- 117 SI: Système International d'Unités
- 118 VPH: Virtual Physiological Human
- 119

120 **INTRODUCTION**

121 Here, we present a draft Minimum Information Standard for recording,
122 annotating, and reporting experimental cardiac electrophysiology data, which we are
123 calling the *Minimum Information about a Cardiac Electrophysiology Experiment*
124 (MICEE) standard. The concept is that for relevant studies, this information will be
125 made available in an online repository and referenced in any related publications.
126 Our hope is that this reporting standard will develop into a tool used by the
127 experimental cardiac electrophysiology community to facilitate and improve
128 recording and dissemination of the minimum information necessary for reproduction
129 of cardiac electrophysiology experimental research, via contextualisation to allow for
130 easier comparison and usage of findings by others, and to enhance the integration of
131 results into other experimental, computational, and conceptual models.

132 Throughout the scientific community, there is growing recognition that open-
133 access data-sharing promotes research transparency, assessment and validation of
134 experimental data, and design of new experiments, furthering discovery from past
135 work and the development of broader computational and/or conceptual models that
136 are based firmly on experimental insight (Smith and Noble, 2008). This is reflected
137 by the current requirements of some funding agencies and journals for data sharing,
138 as well as the concerted efforts of various institutions in its promotion and
139 implementation (Cragin et al., 2010; Nelson, 2009). While there are examples of very
140 useful data sharing resources, such as the *database of Genotypes and Phenotypes*
141 (dbGAP; <http://www.ncbi.nlm.nih.gov/gap/>) for storing genome-wide association
142 study data, or the *Gene Expression Omnibus* (GEO;
143 <http://www.ncbi.nlm.nih.gov/geo/>) for mRNA data, many real and perceived barriers
144 need to be overcome before such resources can achieve their full potential. These

145 include reluctance to contribute community data that has taken years to collect,
146 concerns about data misuse and/or misattribution, worries about intellectual property
147 rights associated with data, and the additional time, effort, and resources required to
148 make data and their contextualisation via meta-data accessible by others (Cragin et
149 al., 2010; Nelson, 2009). An additional fundamental problem is a lack of clear and
150 useful reporting standards and associated infrastructure. Minimum Information
151 Standards and reporting guidelines are now recognized as an important step
152 towards establishing effective data use and re-use, thus optimising data utilisation
153 and enabling experimental reproducibility – something that is already an *explicit*
154 requirement for the scientific research and communication process.

155 Any useful set of reporting standards is necessarily discipline-specific,
156 describing what raw- and meta-data should be made available, and how this should
157 be formatted for general use, so that *necessary and sufficient* information is provided
158 to allow reproduction of experimental interventions and study procedures. While this
159 is critical for well-informed evaluation of results and conclusions, the associated
160 overhead should remain *minimal*, to encourage compliance (Taylor et al., 2007). The
161 identification of a *minimally necessary and sufficient* set of parameters is a difficult
162 task, confounded by the overwhelming diversity of scientific practices and
163 information in any given field.

164 In recent years, there has been a growing interest in identifying formalised
165 reporting requirements for experimental and computational research. Current efforts
166 are being brought together under the *Minimum Information about a Biomedical or*
167 *Biological Investigation* (MIBBI) umbrella (<http://www.mibbi.org/>), aimed at uniting the
168 various communities developing Minimum Information Standards for the description
169 of data sets and the workflows by which they were generated (Kettner et al., 2010;

170 Taylor et al., 2008). Currently, however, no set of reporting standards exist for
171 cardiac electrophysiology experimentation, contributing to a lack of consistency in
172 the information reported upon publication. This has resulted from neither negligence
173 nor ill intent. Constraints on time and resources, as well as outlet-specific content
174 and formatting demands, make the task of reporting in a standardised fashion
175 appear burdensome and (possibly) not worth the extra effort. One might regard it as
176 ironic, that the current mode may in fact be a larger drain on time and resources for
177 the community overall, than the alternative. To reproduce experiments from
178 published methods sections in the literature is, by and large, not possible without in-
179 depth knowledge of all materials, procedures, and interventions (which will be rare in
180 fields with a low proportion of 'routine' research activities). This situation has been
181 made worse by the progressive reduction in space allocated to the description of
182 methods in many journals (in some cases this has been partly remedied by online
183 supplemental information, although standardisation of such sections might still aid
184 experimental reproducibility). Lack of reporting standards also makes it particularly
185 difficult to enable data utilisation across fields, such as by computational modellers
186 who may be less familiar with determinants of experimental studies that are 'at the
187 fringes' of experimental design (while pH or ambient temperature may be obvious
188 parameters to watch out for, osmotic pressure of solutions or the supplier of a
189 transgenic strain may feature less prominently on the list of possible confounding
190 aspects). Furthermore, 'negative' results, *i.e.*, the finding that a particular intervention
191 does not give rise to a hypothesised response, are published far too rarely (even
192 though the only thing 'negative' about these data are that they do not reach the
193 public domain), such that positive results, even when scarce, may dominate
194 perception. This results in an abundance of inadvertently repeated experiments and

195 a profound publication bias that hampers scientific understanding (Schooler, 2011),
196 although there are current efforts to correct this (such as with the *Journal of Negative*
197 *Results in Biomedicine*; <http://www.jnrbm.com/>).

198 Thus, standardised reporting guidelines may help to ensure availability of the
199 information needed to reproduce a study, or to not attempt it, avoiding wasted time
200 and resources, which *increases* overall productivity. Additionally, increased
201 emphasis on the integration of insight from different levels of structural complexity
202 (Kohl et al., 2010), and a renewed focus on the translation of information learned
203 through basic science to the clinic, requires more stringent control and
204 documentation of experimental conditions and protocols (especially important in the
205 post-genomic era, with the increasingly common use of small animal models to
206 mimic human conditions and to explore treatment possibilities). Careful consideration
207 should be paid to what are seemingly inevitable experimental restrictions, such as
208 caused by sub-optimal experimental design, systematic experimental error, and
209 parameter variations outside the control of the experimentalist. This will also benefit
210 efforts to conduct quantitative analysis and computational modelling, by facilitating
211 inclusion of important parameters that potentially influence results, such as factors
212 accounting for subject specific differences (e.g., age and sex). While one cannot
213 predict all of the information that might be necessary for *post hoc* computational
214 and/or conceptual 'modelling' - especially with the rapid evolution of this field -
215 having reported what is currently understood to constitute the most important factors
216 contributing to an experimental outcome will be of significant utility for the
217 identification and validation of novel hypotheses (Greenstein and Winslow, 2011;
218 Rudy, 2000).

219 **PROPOSED DRAFT OF A MINIMUM INFORMATION STANDARD FOR CARDIAC**
220 **ELECTROPHYSIOLOGY EXPERIMENTATION**

221 The goal of this paper is to present a draft of a Minimum Information Standard
222 for cardiac electrophysiology experimentation. This has been modelled after the
223 *Minimum Information about a Neuroscience Investigation* (MINI;
224 <http://www.carmen.org.uk/standards>) standard (Gibson et al., 2009), but tailored for
225 the specific needs of cardiac electrophysiology. It contains a draft of what is believed
226 to be an explicit minimum set of information that is necessary for reproduction of
227 experimental cardiac electrophysiology research and its integration into other
228 experimental or computational models, while hopefully remaining general enough to
229 cover a majority of cases in the field. A significant proportion of this information
230 would normally already appear in the Methods sections of publications. Nonetheless,
231 it has been included here, as having all information in one place will improve
232 efficiency of access. The MICEE standard has been organised into the following five
233 sections, which are believed to encapsulate the most important aspects of the
234 majority of cardiac electrophysiology experiments:

235 **1. Material**

236 **2. Environment**

237 **3. Protocols**

238 **4. Recordings**

239 **5. Analysis**

240 Below we describe the rationale for these sections, and the general information
241 essential to each of them, in order to clarify the content of the proposed draft
242 reporting standard, and to aid broader discussion and further development of the
243 proposal. The complete MICEE draft standard can be found in Appendix A. The

244 described reporting standard is ‘a draft sequence’, and very much open to further
245 development in the light of community needs and preferences. We do not specifically
246 discuss each individual element, but hope that all elements follow from the principles
247 discussed above. Finally, to illustrate the utility of the MICEE standard, an example
248 (using a study recently published by some of the authors (Iribe et al., 2009)) is given
249 in Appendix B, which highlights the need for information not contained in ‘the usual’
250 Methods section.

251 **1. Material:** This section gives details of the subject(s) under investigation.
252 Depending on the nature of the study, the type(s) may be human, whole animal,
253 isolated heart, isolated or engineered tissue, isolated, cultured, or stem cells, or cell
254 fragments (*e.g.*, membrane patches), and subheadings are provided for each. Each
255 of these subheadings has its own specific characteristics, relating to features that are
256 increasingly recognized as important to cardiac electrophysiology (*e.g.*, sex,
257 developmental stage, genetic variation, disease background, and husbandry,
258 including diet, environmental enrichment, and light cycle). Additionally, it includes
259 information about sample preparation and maintenance, focusing on aspects such
260 as method of animal dispatch, anatomical origin of the sample, isolation procedure,
261 cell selection process, and growth, culture, and differentiating conditions. This
262 information is essential to the outcome of cardiac electrophysiology studies, as it is
263 arguably one of the most important acute determinants of the quality, viability, and
264 reproducibility of experimental model systems.

265 **2. Environment:** Information contained in this section, relating to
266 environmental conditions in which an experiment is conducted, is also vital to the
267 interpretation and comparison of cardiac electrophysiology results, but is often not
268 well-controlled or monitored (*e.g.*, ‘room temperature’), with specific details

269 underreported in publications (and perhaps increasingly so, which would be a
270 worrying trend). Included factors range from sample temperature (e.g., temperature
271 at the site of experimentation, not in a fluid reservoir for example) and solution
272 characteristics, to flow rates, bath volume, and details about the presence of
273 chemicals, dyes, gases, or drugs. This not only makes information available for later
274 study verification, but also highlights the importance of a range of parameters for
275 experimental control, potentially encouraging closer monitoring of relevant
276 conditions, where possible.

277 **3. Protocols:** This heading provides a description of the experimental protocols
278 of a study. Including detailed descriptions of experimental procedures is becoming
279 progressively more important, as an increasing number of journals are either
280 reducing the space provided for publishing this information (often due to economical
281 and citation-impact related pressures), or relegating it to electronic add-on
282 resources. It is by necessity less specific than other sections, requiring a *sufficiently*
283 *detailed account of procedures and interventions*, as cardiac electrophysiology
284 draws on an extremely wide array of experimental techniques and model systems,
285 often with laboratories following their own individually-tailored protocols. Also, this is
286 the area where scientific originality is, perhaps, the most important driver of
287 progress. As such, the prescription of a firm reporting standard for information of this
288 type is neither possible nor desirable.

289 **4. Recordings:** This section addresses the specifics of equipment and
290 software used to record and pre-process signals in an experiment, including relevant
291 parameters of operation. The importance of this information may not be as self-
292 evident as other aspects described above, which may result in severe under-
293 reporting in publications. This includes features such as detailed description of timing

294 control, data sampling rates, filtering and smoothing, bit depth, gain, and dynamic
295 range, all of which can greatly affect the nature and information content of data. For
296 example, with patch-clamp recordings, technical aspects are essential for
297 appropriate application of the technique and errors in factors such as series
298 resistance and voltage-clamp control can lead to errors in the basic properties of
299 currents, resulting in misinterpretation of results and misleading conclusions.

300 **5. Analysis:** This part of the reporting standard provides information on the
301 software and methods used in data processing to extract information, including
302 details of *post hoc* filtering, normalisation, interpolation, inclusion/exclusion criteria, *n*
303 number(s), and statistical methods. Its importance is fairly clear, as outcomes can be
304 significantly altered by data manipulation, but still, detail provided in publications
305 tends to be insufficient for adequate reproduction. An additional feature of this
306 section is the inclusion of example(s) of raw and processed data (from the same
307 recording), which will allow others to assess whether they are able to replicate
308 described approaches (and which is also often omitted from publications).

309 **IMPLEMENTING AND DEVELOPING THE MICEE STANDARD**

310 It is important to repeat that this reporting standard is meant, in its present form,
311 *as a place to start*. The set of minimum information must develop from experience
312 and input from the greater community, which may include both growth and reduction
313 of currently envisaged categories and parameters. The hope is that, with time,
314 adherence to minimum reporting standards will become second nature, as is the
315 current expectation that the composition of solutions and their pH form part of any
316 methods section in this field. This would help to address some of the challenges
317 associated with data sharing, experimental reproducibility, model interrelation, and
318 correlation of experimental and computational studies in cardiac electrophysiology

319 research. The concept is also that the MICEE repository, discussed below, will allow
320 for dissemination of unpublished (and thus less publically available) results, such as
321 those described in PhD theses and unreported 'negative' findings. This may avoid
322 repetition of experiments and improve scientific understanding, and when pertinent,
323 can be cited in future publications.

324 Progress could be facilitated by a research program to catalogue past work
325 (similar to what has been done for a single recent study in Appendix B). Such shared
326 access to 'retrospective' communications has been developed, with significant
327 success, for computational cardiac electrophysiology models, which is benefiting
328 from the increasing use of a standardised format for communication and modelling
329 (Nickerson and Buist, 2009), called *Cell Markup Language* (CellML) (Cuellar et al.,
330 2003). The CellML model repository now contains over 250 cardiac
331 electrophysiology cell models (see <http://models.cellml.org/electrophysiology/>),
332 curated and tested to different levels, making models and associated meta-data (like
333 original publications) easily accessible.

334 Once the reporting standard begins to converge, it will be important to
335 incorporate it into the MIBBI framework (see
336 <http://www.mibbi.org/index.php/Projects/MICEE>) and to work with other communities
337 to explore standardized nomenclatures and combined workflow elements, to avoid
338 double work and incompatibility of outputs. For instance, the *Virtual Physiological*
339 *Human* (VPH) (Fenner et al., 2008; Hunter et al., 2010; Hunter and Viceconti, 2009;
340 Kohl and Noble, 2009) and *Physiome* (Bassingthwaighte et al., 2009;
341 Bassingthwaighte, 1997; Hunter et al., 2002; Smith et al., 2009) projects are
342 promoting the development of model and data encoding standards for the
343 computational modelling community, along with their associated minimum

344 information requirements. Efforts are also underway to establish uniform data
345 standards for clinical cardiovascular electrophysiology studies and procedures, to
346 serve as a basis for research and practice databases (Buxton et al., 2006; Weintraub
347 et al., 2011). It will be essential to promote compatibility with these activities,
348 especially for use of experimental data in computational model building and
349 validation. Additionally, it could prove helpful if the formal reporting standard – once
350 endorsed more broadly by the community – would be adopted by one or more
351 professional societies. Equally crucial will be the question whether leading journals in
352 the field may be convinced to identify ‘MICEE-compatible data reporting’ as a
353 desirable approach.

354 Most importantly, beyond the desire to increase awareness of the need for
355 Minimum Information Standards in cardiac electrophysiology experimentation, we
356 intend to initiate action. Thus, the authors of this communication are making a
357 commitment to adhere to the proposed reporting standard for a twelve-month period,
358 starting at the beginning of 2012, by recording the then identified MICEE information
359 for all of their relevant studies. Upon study completion, this information will be made
360 available in a repository maintained by the *Johns Hopkins University CardioVascular*
361 *Research Grid* (accessible at <http://www.micee.org/>). When relevant, MICEE entries
362 will link-out to the digital object identifiers (DOI) of publications, and be referenced in
363 the related papers with a citable identification. This test of utility will help in assessing
364 and shaping the MICEE approach, and we invite others in the community to join us
365 in this effort. We also request feedback on how the reporting standard might be
366 improved, which will be possible *via* a public notice board on the MICEE.org website,
367 to facilitate community discussion. Finally, once the standard begins to gain broader
368 acceptance by cardiac electrophysiologists, an oversight committee will be

369 established to manage the process of standard refinement and future extensions of
370 MICEE.

371 **PRESENT DIFFICULTIES AND CHALLENGES AHEAD**

372 Even amongst those who believe Minimum Information Standards are
373 necessary and important, a common argument against their development is that “it is
374 a nearly impossible task”. Other valid criticisms include the concern that their
375 implementation is associated with too much work, or – conversely – that they do not
376 go far enough. However, if one regards the *status quo* as not ideal, it is hard to argue
377 that useful progress could not be made. It is obvious that emergence of a complete
378 consensus by a research community on any reporting standard is highly unlikely.
379 This applies to the proposed MICEE standard, and it includes the authors of this
380 paper. There is, however, agreement amongst the authors that there is a need to
381 agree on, and define (standardise) the minimum information needs for cardiac
382 electrophysiology experimentation. We realise that a complete description of any
383 experiment is unachievable, but believe that the proposed standard encompasses
384 key features necessary for the effective use of information by other researchers.
385 Besides, ‘exact’ repetition of an experiment with identical conditions, even by the
386 original experimentalist, is in itself improbable (and not usually warranted or desired).
387 Proper documentation of the factors that may be most important to experimental
388 outcomes, however, is an attainable and relevant goal.

389 It is clear that convergence to an agreement on a ‘final’ MICEE standard will
390 need time, but once a standard has been accepted, the question remains as to the
391 best ways of encouraging ‘compliance’. As with most change, a combination of ‘stick
392 and carrot’ tends to be most productive. Wielding the stick, one could imagine an
393 approach where those who have the authority demand compliance. Examples would

394 include funding agencies (which can make it a condition of support), scientific
395 societies (which can establish it as a precedent), and journals (which can make it
396 part of publication policies, or simply formalise their methods sections and online
397 supplements to provide information congruent to the proposed standard). By and
398 large, it seems that scientists generally do not respond well to (new) dogmas and
399 demands, as even widely accepted (and exceedingly valuable) precedents, for
400 instance the *système international d'unités* (SI), have had (and still have) a hard time
401 to penetrate certain traditional barriers. Ultimately, the key question is: “what is in it
402 for me?”. If and when a new tool (e.g., a reporting standard) proves to be productive
403 and has clear value, for example saving time, effort, and resources, it turns itself into
404 the ‘carrot’. A useful example of this is the now widely-accepted standardisation
405 approach in the Systems Biology field, the *Systems Biology Markup Language*
406 (SBML) (Hucka et al., 2003).

407 The trick, then, will be to develop MICEE to a level where it becomes a tool of
408 utility. Therefore, the MICEE standard is a form of self-regulation, shaped by the
409 greater community, such that the final product will be formed by end-users, with the
410 aim of making it a useful time saving measure, rather than a hindrance. In this
411 context, the goal is also for it to be useful for researchers in creating ‘internal’ meta-
412 data collections for continued work, sharing among collaborators, and eventual
413 publication. This will be additionally important for its effectiveness as a time saving
414 device, as collection of data at-the-time-of-study will facilitate its later dissemination.
415 For this, a scientist controlled embargo system will be essential (Cragin et al., 2010),
416 and emulating the functionality of existing ‘staging repository’ tools, such as the Data
417 Staging Repository (DataStar; <http://datastar.mannlib.cornell.edu/>), may be a
418 constructive approach.

419 Attitudes towards reporting standards and their implementation are changing in
420 many other areas of bioscience research, spearheaded by an active and organised
421 minimum information community: the MIBBI portal currently lists 32 Minimum
422 Information Standards (see http://www.mibbi.org/index.php/MIBBI_portal). Common
423 to those reporting standards that have been successful is the availability of technical
424 support, in the form of software for formatting experimental data and recording
425 associated meta-data and repositories for deposition, storage, and retrieval of this
426 information, including software and user-interfaces for efficient database searches
427 and data exportation (with links to publications and cross-links to other experiments
428 and sources of information). In general, there are three necessary elements for
429 reporting standard utilisation: (i) definition of the Minimum Information Standard, (ii) a
430 syntax for expression of data, and (iii) a meta-data standard for semantics (*via*
431 ontologies to ensure the use of accepted terminology). Our aim, at this point, is to
432 propose and develop (i). In the near future, this will need to be followed by (ii) and
433 (iii), to ensure efficient automated search processes. For this, an XML-based
434 standard for time varying data will be useful, such as is being developed through the
435 *BioSignal Markup Language* (BioSignalML) (Brooks, 2009). Ultimately, further
436 development will require a commitment from national, regional, and/or private
437 funding agencies, and while resources are always in short supply, cost-benefit
438 considerations suggest that this would be in the best interest of all involved.

439 As always, it is helpful to try to learn from the experience of previous minimum
440 information efforts. The pioneering, and maybe most successful, example of a
441 reporting standard was published 10 years ago, the *Minimum Information About a*
442 *Microarray Experiment* (MIAME) standard (Brazma et al., 2001). The assertion at the
443 time was that, to make data usable for analysis, everything relevant had to be

444 recorded systematically (Brazma, 2009). Perhaps most important to its success was
445 the fact that a majority of scientific journals made submission of MIAME-compliant
446 data to public repositories mandatory. Also essential was its intuitive interface, where
447 users could place queries to search databases. The relevant databases (for instance
448 dbGAP), curate, analyse, and transform microarray data, making it widely
449 accessible. However, even with the general adoption of MIAME principles, it can be
450 difficult to obtain desired microarray data (Ioannidis et al., 2009), which has been
451 attributed mainly to the fact that the initial lack of a standard computer-readable
452 formats for representing information has limited its utility (Brazma, 2009). This has
453 been improved by specification of formats by the *Functional Genomics Data (FGED)*
454 *Society* (<http://www.mged.org/>, which was founded in 1999 as the *Microarray Gene*
455 *Expression Data (MGED) Society*). Another lesson has been that it is important to
456 allow 'inheritance' of database information, and to ease linking with previously
457 published resources (e.g., via PubMed). Protocol description should be facilitated,
458 wherever possible, by use of standard templates, or reuse of existing protocols (with
459 optional modifications). However, care must be taken not to lose information
460 regarding the rationale behind a researcher's experimental choices, such as study
461 design, conditions, and protocols, as this is critically important for understanding.
462 Such meta-data may not come across checklists and tables, but rather only through
463 original narrative, so appropriate use of freeform text fields is essential, especially for
464 protocol description. Furthermore, it is conceivable that codification of reporting
465 might promote adoption of preset patterns that could impact imagination and
466 creativity. So, a workable compromise must be sought, as loosely prescribed
467 sections may encourage substitution of jargon, abbreviation, shorthand, and
468 ambiguously terse description for a full explanation. Related to this is the worry that,

469 as a secondary source implemented in an online database, MICEE data will be
470 subject to errors, omissions, and misrepresentations that would not occur with peer-
471 reviewed publication. Peer-reviewed publications are not free of inaccuracies
472 themselves, of course, and the only truly reliable source is the 'original' – the
473 investigator who performed the studies. Discrepancies between peer-review and
474 MICEE reporting would be minimised by explicitly linking publication of papers and
475 database sets. Curation of the MICEE database will remain a critical issue
476 (experience with other repositories, for instance the CellML model repository, has
477 shown that only verified entries tend to be reliable sources), especially for studies
478 without an associated publication, and a mechanism for report checking will need to
479 be developed. These are all areas where it will be useful to adopt technologies
480 already under development or in use by the MIBBI community.

481 **CONCLUSION**

482 The time is ripe for open-access sharing of published data in the cardiac
483 electrophysiology community. The field would benefit from Minimum Information
484 Standards and reporting guidelines. Successful efforts in other research areas have
485 hinged on general acceptance of, and compliance to, such reporting standards.
486 Cardiac experimental electrophysiology does not currently have a well-defined
487 Minimum Information Standard, and as a step toward establishing this, we propose
488 the *Minimum Information about a Cardiac Electrophysiology Experiment* (MICEE;
489 see the draft presented in Appendix A, for consideration and development by the
490 greater community). A considered user interface is hoped to make compliance as
491 pain-free as possible, and we hope that with time this approach will manifest itself as
492 an improvement over current practice. As an initial test of its utility, during 2012, the
493 authors of this communication will adhere to the then identified standard, and we

494 invite the reader to join this effort, by evaluating and implementing the *Minimum*
495 *Information about a Cardiac Electrophysiology Experiment* standard.

496

497 **ACKNOWLEDGEMENTS**

498 This work is supported by the Engineering and Physical Science Research Council
499 of the United Kingdom, the British Heart Foundation, the European Commission FP7
500 Virtual Physiological Human Initiative (Network of Excellence, preDiCT, euHeart),
501 and National Institutes of Health grants U54HG004028, R01HL103727, and
502 R24HL085343.

503

504 **EDITORS' NOTE**

505 Please see also related communications in this issue by Cooper et al. (2011) and

506 Winslow et al. (2011).

507

508 **REFERENCES**

509

510 Bassingthwaighe, J., Hunter, P. and Noble, D. (2009) The Cardiac Physiome:
511 perspectives for the future. *Exp Physiol* **94**, 597-605.

512 Bassingthwaighe, J. B. (1997) Design and strategy for the Cardionome Project. *Adv*
513 *Exp Med Biol* **430**, 325-39.

514 Brazma, A. (2009) Minimum Information About a Microarray Experiment (MIAME)--
515 successes, failures, challenges. *ScientificWorldJournal* **9**, 420-3.

516 Brazma, A., Hingamp, P., Quackenbush, J., Sherlock, G., Spellman, P., Stoeckert,
517 C., Aach, J., Ansorge, W., Ball, C. A., Causton, H. C., Gaasterland, T.,
518 Glenisson, P., Holstege, F. C., Kim, I. F., Markowitz, V., Matese, J. C.,
519 Parkinson, H., Robinson, A., Sarkans, U., Schulze-Kremer, S., Stewart, J.,
520 Taylor, R., Vilo, J. and Vingron, M. (2001) Minimum information about a
521 microarray experiment (MIAME)-toward standards for microarray data. *Nat*
522 *Genet* **29**, 365-71.

523 Brooks, D. (2009) Extensible biosignal metadata: a model for physiological time-
524 series data. *Conf Proc IEEE Eng Med Biol Soc* **2009**, 3881-4.

525 Buxton, A. E., Calkins, H., Callans, D. J., DiMarco, J. P., Fisher, J. D., Greene, H. L.,
526 Haines, D. E., Hayes, D. L., Heidenreich, P. A., Miller, J. M., Poppas, A.,
527 Prystowsky, E. N., Schoenfeld, M. H., Zimetbaum, P. J., Goff, D. C., Grover, F.
528 L., Malenka, D. J., Peterson, E. D., Radford, M. J. and Redberg, R. F. (2006)
529 ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological
530 studies and procedures: a report of the American College of
531 Cardiology/American Heart Association Task Force on Clinical Data Standards
532 (ACC/AHA/HRS Writing Committee to Develop Data Standards on
533 Electrophysiology). *Circulation* **114**, 2534-70.

534 Cooper, J., Corrias, A., Gavaghan, D., Noble, D. (2011) Considerations for the use of
535 cellular electrophysiology models within cardiac tissue simulations. *Prog Biophys*
536 *Mol Biol* **NUMBER**, pp-pp. [note to publisher: please update before print]

537 Cragin, M. H., Palmer, C. L., Carlson, J. R. and Witt, M. (2010) Data sharing, small
538 science and institutional repositories. *Philos Transact A Math Phys Eng Sci* **368**,
539 4023-38.

540 Cuellar, A. A., Lloyd, C. M., Nielsen, P. F., Bullivant, D. P., Nickerson, D. P. and
541 Hunter, P. J. (2003) An overview of CellML 1.1, a biological model description
542 language. *Simulation* **79**, 740-7.

543 Fenner, J. W., Brook, B., Clapworthy, G., Coveney, P. V., Feipel, V., Gregersen, H.,
544 Hose, D. R., Kohl, P., Lawford, P., McCormack, K. M., Pinney, D., Thomas, S.
545 R., Van Sint Jan, S., Waters, S. and Viceconti, M. (2008) The EuroPhysiome,
546 STEP and a roadmap for the virtual physiological human. *Philos Transact A*
547 *Math Phys Eng Sci* **366**, 2979-99.

- 548 Gibson, F., Overton, P., Smulders, T., Schultz, S., Eglén, S., Ingram, C., Panzeri, S.,
549 Bream, P., Whittington, M., Sernagor, E., Cunningham, M., Adams, C.,
550 Echtermeyer, C., Simonotto, J., Kaiser, M., Swan, D., Fletcher, M. and Lord, P.
551 (2009) Minimum Information about a Neuroscience Investigation (MINI):
552 Electrophysiology. *Nature Precedings*,
553 <http://hdl.handle.net/10101/npre.2009.1720.2>.
- 554 Greenstein, J. L. and Winslow, R. L. (2011) Integrative systems models of cardiac
555 excitation-contraction coupling. *Circ Res* **108**, 70-84.
- 556 Hucka, M., Finney, A., Sauro, H. M., Bolouri, H., Doyle, J. C., Kitano, H., Arkin, A. P.,
557 Bornstein, B. J., Bray, D., Cornish-Bowden, A., Cuellar, A. A., Dronov, S., Gilles,
558 E. D., Ginkel, M., Gor, V., Goryanin, I., Hedley, W. J., Hodgman, T. C., Hofmeyr,
559 J. H., Hunter, P. J., Juty, N. S., Kasberger, J. L., Kremling, A., Kummer, U., Le
560 Novere, N., Loew, L. M., Lucio, D., Mendes, P., Minch, E., Mjolsness, E. D.,
561 Nakayama, Y., Nelson, M. R., Nielsen, P. F., Sakurada, T., Schaff, J. C.,
562 Shapiro, B. E., Shimizu, T. S., Spence, H. D., Stelling, J., Takahashi, K., Tomita,
563 M., Wagner, J. and Wang, J. (2003) The systems biology markup language
564 (SBML): a medium for representation and exchange of biochemical network
565 models. *Bioinformatics* **19**, 524-31.
- 566 Hunter, P., Coveney, P. V., de Bono, B., Diaz, V., Fenner, J., Frangi, A. F., Harris,
567 P., Hose, R., Kohl, P., Lawford, P., McCormack, K., Mendes, M., Omholt, S.,
568 Quarteroni, A., Skar, J., Tegner, J., Randall Thomas, S., Tollis, I., Tsamardinou,
569 I., van Beek, J. H. and Viceconti, M. (2010) A vision and strategy for the virtual
570 physiological human in 2010 and beyond. *Philos Transact A Math Phys Eng Sci*
571 **368**, 2595-614.
- 572 Hunter, P., Robbins, P. and Noble, D. (2002) The IUPS human Physiome Project.
573 *Pflugers Arch* **445**, 1-9.
- 574 Hunter, P. J. and Viceconti, M. (2009) The VPH-Physiome Project: Standards and
575 Tools for Multiscale Modeling in Clinical Applications. *IEEE Rev Biomed Eng* **2**,
576 40-53.
- 577 Ioannidis, J. P., Allison, D. B., Ball, C. A., Coulibaly, I., Cui, X., Culhane, A. C.,
578 Falchi, M., Furlanello, C., Game, L., Jurman, G., Mangion, J., Mehta, T.,
579 Nitzberg, M., Page, G. P., Petretto, E. and van Noort, V. (2009) Repeatability of
580 published microarray gene expression analyses. *Nat Genet* **41**, 149-55.
- 581 Iribe, G., Ward, C. W., Camelliti, P., Bollensdorff, C., Mason, F., Burton, R. A.,
582 Garry, A., Morphew, M. K., Hoenger, A., Lederer, W. J. and Kohl, P. (2009) Axial
583 stretch of rat single ventricular cardiomyocytes causes an acute and transient
584 increase in Ca²⁺ spark rate. *Circ Res* **104**, 787-95.
- 585 Kettner, C., Field, D., Sansone, S. A., Taylor, C., Aerts, J., Binns, N., Blake, A.,
586 Britten, C. M., de Marco, A., Fostel, J., Gaudet, P., Gonzalez-Beltran, A., Hardy,
587 N., Hellemans, J., Hermjakob, H., Juty, N., Leebens-Mack, J., Maguire, E.,
588 Neumann, S., Orchard, S., Parkinson, H., Piel, W., Ranganathan, S., Rocca-
589 Serra, P., Santarsiero, A., Shotton, D., Sterk, P., Untergasser, A. and Whetzel,
590 P. L. (2010) Meeting Report from the Second "Minimum Information for

- 591 Biological and Biomedical Investigations" (MIBBI) workshop. *Stand Genomic Sci*
592 **3**, 259-66.
- 593 Kohl, P., Crampin, E. J., Quinn, T. A. and Noble, D. (2010) Systems biology: an
594 approach. *Clin Pharmacol Ther* **88**, 25-33.
- 595 Kohl, P. and Noble, D. (2009) Systems biology and the virtual physiological human.
596 *Mol Syst Biol* **5**, 292.
- 597 Nelson, B. (2009) Data sharing: empty archives. *Nature* **461**, 160-3.
- 598 Nickerson, D. P. and Buist, M. L. (2009) A physiome standards-based model
599 publication paradigm. *Philos Transact A Math Phys Eng Sci* **367**, 1823-44.
- 600 Rudy, Y. (2000) From genome to physiome: integrative models of cardiac excitation.
601 *Ann Biomed Eng* **28**, 945-50.
- 602 Schooler, J. (2011) Unpublished results hide the decline effect. *Nature* **470**, 437.
- 603 Smith, N. and Noble, D. (2008) Knowledge capture and the responsibility: past and
604 present. *Prog Biophys Mol Biol* **96**, 1-2.
- 605 Smith, N. P., Hunter, P. J. and Paterson, D. J. (2009) The Cardiac Physiome: at the
606 heart of coupling models to measurement. *Exp Physiol* **94**, 469-71.
- 607 Taylor, C. F., Field, D., Sansone, S. A., Aerts, J., Apweiler, R., Ashburner, M., Ball,
608 C. A., Binz, P. A., Bogue, M., Booth, T., Brazma, A., Brinkman, R. R., Michael
609 Clark, A., Deutsch, E. W., Fiehn, O., Fostel, J., Ghazal, P., Gibson, F., Gray, T.,
610 Grimes, G., Hancock, J. M., Hardy, N. W., Hermjakob, H., Julian, R. K., Jr.,
611 Kane, M., Kettner, C., Kinsinger, C., Kolker, E., Kuiper, M., Le Novere, N.,
612 Leebens-Mack, J., Lewis, S. E., Lord, P., Mallon, A. M., Marthandan, N.,
613 Masuya, H., McNally, R., Mehrle, A., Morrison, N., Orchard, S., Quackenbush, J.,
614 Reecy, J. M., Robertson, D. G., Rocca-Serra, P., Rodriguez, H., Rosenfelder, H.,
615 Santoyo-Lopez, J., Scheuermann, R. H., Schober, D., Smith, B., Snape, J.,
616 Stoeckert, C. J., Jr., Tipton, K., Sterk, P., Untergasser, A., Vandesompele, J. and
617 Wiemann, S. (2008) Promoting coherent minimum reporting guidelines for
618 biological and biomedical investigations: the MIBBI project. *Nat Biotechnol* **26**,
619 889-96.
- 620 Taylor, C. F., Paton, N. W., Lilley, K. S., Binz, P. A., Julian, R. K., Jr., Jones, A. R.,
621 Zhu, W., Apweiler, R., Aebersold, R., Deutsch, E. W., Dunn, M. J., Heck, A. J.,
622 Leitner, A., Macht, M., Mann, M., Martens, L., Neubert, T. A., Patterson, S. D.,
623 Ping, P., Seymour, S. L., Souda, P., Tsugita, A., Vandekerckhove, J., Vondriska,
624 T. M., Whitelegge, J. P., Wilkins, M. R., Xenarios, I., Yates, J. R., 3rd and
625 Hermjakob, H. (2007) The minimum information about a proteomics experiment
626 (MIAPE). *Nat Biotechnol* **25**, 887-93.
- 627 Winslow, R. L., Greenstein, J. L. (2011) Cardiac myocytes and local signaling in
628 nano-domains. *Prog Biophys Mol Biol* **NUMBER**, pp-pp. [note to publisher:
629 please update before print]

630 Weintraub, W. S., Karlsberg, R. P., Tchong, J. E., Boris, J. R., Buxton, A. E., Dove,
631 J. T., Fonarow, G. C., Goldberg, L. R., Heidenreich, P., Hendel, R. C., Jacobs, A.
632 K., Lewis, W., Mirro, M. J. and Shahian, D. M. (2011) ACCF/AHA 2011 Key Data
633 Elements and Definitions of a Base Cardiovascular Vocabulary for Electronic
634 Health Records: A Report of the American College of Cardiology
635 Foundation/American Heart Association Task Force on Clinical Data Standards.
636 *Circulation*.

637

638

639 **APPENDIX A**

640

641 **Proposed Minimum Information Standard: *Minimum Information about a Cardiac***
642 ***Electrophysiology Experiment (MICEE)***

643

644 **1. Material**

645 1.1 Type (Human / Whole Animal / Isolated Heart / Isolated Tissue / Isolated Cells / Cell

646 Fragments / Engineered Tissue / Cultured Cells / Stem Cells)

647 1.2 Ethical approval

648 1.3 Human

649 1.3.1 Gender

650 1.3.2 Age / developmental stage / body mass index

651 1.3.3 Clinical information / disease background (health status / known pathology / drug

652 treatment / *etc.*)

653 1.3.4 Genetic variation

654 1.3.5 Familial history / pedigree

655 1.3.6 Point within circadian cycle / point within hormonal cycle

656 1.3.7 Conscious/sedated/anesthetised (agent(s) / supplier(s) / *etc.*) / open/closed chest /

657 acute/chronic intervention

658 1.4 Whole Animal / Isolated Heart / Isolated Tissue / Isolated Cells / Cell Fragments

659 1.4.1 Gender

660 1.4.2 Age / developmental stage / weight

661 1.4.3 Genus / species / strain

662 1.4.4 Supplier

663 1.4.5 Genetic variation (type / means)

664 1.4.6 Disease model / state (type / means / assessment)

665 1.4.7 Husbandry (diet / housing type / environmental enrichment / day-night cycle / *etc.*)

666 1.4.8 Point within circadian cycle / point within hormonal cycle

667 1.4.9 Conscious/sedated/anesthetised (agent(s) / supplier(s) / *etc.*) / open/closed chest /

668 acute/chronic intervention

669 1.4.10 Method of animal dispatch

670 1.4.11 Anatomical origin of sample

671 1.4.12 Isolation procedure

672 1.4.13 Time and method to final preparation (temperature / solution / electrical/mechanical

673 stimulation / mode of storage / *etc.*)

674 1.4.14 Isolated heart mode of operation (working or Langendorff / constant pressure or flow /

675 balloon / *etc.*)

676 1.4.15 Cell selection process / single cell confirmation / morphological status before/during

677 recordings

678 1.5 Engineered Tissue

679 1.5.1 Cellular/acellular composition

- 680 1.5.2 Growth conditions (time / temperature / medium / substrate / structure / bioreactor /
681 supplements / electrical/mechanical stimulation / mode of storage / *etc.*)
- 682 1.6 Cultured Cells
- 683 1.6.1 Cell line
- 684 1.6.2 Source / anatomical origin of sample
- 685 1.6.3 Passage (number / conditions / density / *etc.*)
- 686 1.6.4 Culture conditions (time / temperature / medium / gas / substrate / structure / supplements
687 / electrical/mechanical stimulation / mode of storage / *etc.*)
- 688 1.6.5 Cell selection process / single cell confirmation / morphological status before/during
689 recordings
- 690 1.7 Stem Cells
- 691 1.7.1 Source / anatomical origin of sample
- 692 1.7.2 Passage (number / conditions / density / *etc.*)
- 693 1.7.3 Culture/differentiating conditions (time / temperature / medium / gas / substrate / structure
694 / supplements / electrical/mechanical stimulation / mode of storage / *etc.*)
- 695 1.7.4 Cell selection process / single cell confirmation / morphological status before/during
696 recordings
- 697 **2. Environment**
- 698 2.1 Sample temperature
- 699 2.2 Gas partial pressures
- 700 2.3 Solution (composition / buffer / pH / osmolarity / *etc.*)
- 701 2.4 Flow rates
- 702 2.5 Bath volume
- 703 2.6 Chemicals/dyes/drugs (concentration(s) / supplier(s) / solvent(s) / *etc.*)
- 704 **3. Protocols**
- 705 3.1 Study design (randomisation / blinding / subject/preparation inclusion/exclusion criteria /
706 number of subjects/preparations / number of rejected subjects/preparations / number of
707 subject/preparation replacements / *etc.*)
- 708 3.2 Sufficiently detailed account of procedures and interventions for offsite reproduction of study by
709 providing time resolved protocols (indication of intervention/recording timings / recordings of
710 baseline/intervention/washout / *etc.*)
- 711 **4. Recordings**
- 712 4.1 Time window of recording
- 713 4.2 Spatial location of recording
- 714 4.3 Electrical Recordings
- 715 4.3.1 Equipment (electrodes / pre-amplifiers / amplifiers / recorders / *etc.*)
- 716 4.3.2 A/D conversion (sampling rate / channels / bit depth / gain / dynamic range / *etc.*)
- 717 4.4 Optical Measurements
- 718 4.4.1 Equipment (optical mapping system / microscope / light sources / filters / lenses / lens
719 numerical aperture / detector specifications / *etc.*)

- 720 4.4.2 Settings (pinhole / gain / offset / spatial and temporal sampling / scan modes / *etc.*)
- 721 4.5 Other Recordings
- 722 4.5.1 Equipment (probes / pre-amplifiers / amplifiers / recorders / *etc.*)
- 723 4.5.2 A/D conversion (sampling rate / channels / bit depth / gain / dynamic range / *etc.*)
- 724 4.6 Timing control (for multiple recording systems / stimulation / recording / imaging *etc.*)
- 725 4.7 Hardware based data processing (filtering / smoothing / binning / *etc.*)
- 726 4.8 Software environment (operating system / acquisition program version / supplier / *etc.*)

727 **5. Analysis**

- 728 5.1 Software environment (operating system / program version/supplier / *etc.*)
- 729 5.2 n number(s) (number of preparations/observations / number of preparations/observations per
- 730 subject / *etc.*)
- 731 5.3 Observations inclusion/exclusion criteria / number of rejected observations
- 732 5.4 Signal-to-noise (method of calculation / *etc.*)
- 733 5.5 Software based data processing (filtering / smoothing / binning / averaging / background signal
- 734 removal / normalisation / interpolation / extrapolation / deconvolution / *etc.*)
- 735 5.6 Calculated parameters (QT-interval / QRS duration / endocardial activation / conduction
- 736 velocity / action potential duration to specified level of repolarisation / peak current / *etc.*)
- 737 5.7 Sufficiently detailed description of statistical methods for offsite reproduction
- 738 5.8 Example(s) of raw and processed data (from the same recording)
- 739

740 **APPENDIX B**

741

742 **Illustration of the utility of the proposed draft standard by application to a previously**
743 **published study.**

744

745 **Green** text represents information available in the publication (or referenced publications). **Amber** text
746 represents information that was recorded at the time of the study and is available upon request, but
747 not made publically available. **Unavailable** indicates information that was either not recorded at the
748 time of the study or is unavailable to the current authors, hindering post-assessment. Categories
749 which do not apply to the present study have been excluded. Both **Amber** and **Red** text highlight the
750 need for a Minimum Information Standard.

751

752 Iribe, G., Ward, C. W., Camelliti, P., Bollensdorff, C., Mason, F., Burton, R. A., Garny, A., Morpew,
753 M. K., Hoenger, A., Lederer, W. J. and Kohl, P. (2009) Axial stretch of rat single ventricular
754 cardiomyocytes causes an acute and transient increase in Ca²⁺ spark rate. *Circ Res* 104, 787-95.
755

756 **1. Material**

757 1.1 Type (Human / Whole Animal / Isolated Heart / Isolated Tissue / Isolated Cells / Cell

758 Fragments / Engineered Tissue / Cultured Cells / Stem Cells)

759 - **Isolated Cells**

760 1.2 Ethical approval

761 - **Experiments conducted in accordance with the guidelines of relevant institutional animal care**
762 **and ethics regulations and in agreement with the UK Home Office Animals (Scientific**
763 **Procedures) Act of 1986**

764 1.4 Whole Animal / Isolated Heart / Isolated Tissue / Isolated Cells / Cell Fragments

765 1.4.1 Gender

766 - **Unavailable**

767 1.4.2 Age / developmental stage / weight

768 - **Unavailable**

769 1.4.3 Genus / species / strain

770 - **Unavailable**

771 1.4.4 Supplier

772 - **Unavailable**

773 1.4.7 Husbandry (diet / housing type / environmental enrichment / day-night cycle / etc.)

774 - **Unavailable**

775 1.4.8 Point within circadian cycle / point within hormonal cycle

776 - **Unavailable**

777 1.4.10 Method of animal dispatch

778 - **Terminally anaesthetised by pentobarbital injection (100 mg/kg)**

779 1.4.11 Anatomical origin of sample

780 - **Ventricle**

781 1.4.12 Isolation procedure

782 - **Enzymatic dissociation (at ~37°C), as described in Mitra, R. and Morad, M. (1985) A uniform**
783 **enzymatic method for dissociation of myocytes from hearts and stomachs of vertebrates.**

784 ***Am J Physiol* 249, H1056–60.**

785 1.4.13 Time and method to final preparation (temperature / solution / electrical/mechanical
786 stimulation / mode of storage / etc.)

787 - Time: 20 minutes for enzymatic dissociation / Temperature: room temperature (~22°C) /
788 Solution: normal Tyrode

789 1.4.15 Cell selection process / single cell confirmation / morphological status before/during
790 recordings

791 - Unavailable

792 2. Environment

793 2.1 Sample temperature

794 - Unavailable

795 2.2 Gas partial pressures

796 - Unavailable

797 2.3 Solution (composition / buffer / pH / osmolarity / etc.)

798 a) Enzymatic dissociation solution A: Composition (in mmol/L): NaCl 135, KCl 5.4, MgCl₂ 1,
799 NaH₂PO₄ 0.33, NaOH / Buffer: 10 mmol/L HEPES / pH: Tolerance = 7.4±0.2 / Osmolarity:
800 Tolerance = 300±10 mOsm/L

801 b) Enzymatic dissociation solution B: Composition: 50 mg collagenase I + 7 mg protease XIV in
802 25 mL enzymatic dissociation solution A / Buffer: Same as solution A / pH: Same as solution
803 A / Osmolarity: Same as solution A

804 c) Enzymatic dissociation solution C: Composition (in mmol/L): Enzymatic dissociation solution A
805 + CaCl₂ / Buffer: Same as solution A / pH: Same as solution A / Osmolarity: Same as solution
806 A

807 d) Normal Tyrode solution: Composition (in mmol/L): NaCl 140, KCl 10, CaCl₂ 1.8, MgCl₂ 1,
808 glucose 11 / Buffer: 5 mmol/L HEPES / pH: Tolerance = 7.4±0.2 / Osmolarity: Tolerance =
809 300±10 mOsm/L

810 e) Na⁺/Ca²⁺-free solution: Composition (in mmol/L): LiCl 140, KCl 10, EGTA 10, MgCl₂ 1,
811 glucose 11 / Buffer: 5 mmol/L HEPES / pH: Tolerance = 7.4±0.2 / Osmolarity: Tolerance =
812 300±10 mOsm/L

813 f) Fixation solution: Composition: PBS containing 2% glutaraldehyde

814 g) Post-fixation solution: Composition: 1% OsO₄

815 2.5 Bath volume

816 - IonOptix Microscope Chamber <0.5 mL

817 2.6 Chemicals/dyes/drugs (concentration(s) / supplier(s) / solvent(s) / etc.)

818 a) Stretch-activated ion channel blocker: *Grammostola spatulata* mechanotoxin-4 /
819 Concentration: 2 μmol/L / Supplier: Peptide Institute, Osaka, Japan / Solvent: Double distilled
820 H₂O

821 b) Intracellular calcium indicator: Fluo-4-acetoxymethyl-ester / Concentration: 5 μmol/L /
822 Supplier: Invitrogen, Carlsbad, CA / Solvent: Dimethyl sulfoxide

823 c) Nitric oxide synthase inhibitor: N^G-nitro-L-arginine methyl ester / Concentration: 1 mmol/L /
824 Supplier: Sigma-Aldrich, St. Louis, USA / Solvent: Double distilled H₂O

825 d) Microtubule polymerisation inhibitor: Colchicine / Concentration: 10 $\mu\text{mol/L}$ / Supplier: Sigma-
 826 Aldrich, St. Louis, USA / Solvent: Double distilled H_2O

827 3. Protocols

828 3.1 Study design (randomisation / blinding / subject/preparation inclusion/exclusion criteria /
 829 number of subjects/preparations / number of rejected subjects/preparations / number of
 830 subject/preparation replacements / *etc.*)

831 - Non-randomised / Non-blinded

832 3.2 Sufficiently detailed account of procedures and interventions for offsite reproduction of study by
 833 providing time resolved protocols (indication of intervention/recording timings / recordings of
 834 baseline/intervention/washout / *etc.*)

835 a) Axial Stretch:

- 836 - Pair of carbon fibres attached to single isolated cardiomyocyte using two 3-axis miniature
- 837 hydraulic manipulators (SM-28, Narishige, Tokyo, Japan), each mounted on separate
- 838 computer-controlled piezoelectric translators (PZT; P-621.1CL, Physik Instrumente,
- 839 Karlsruhe/Palmbach, Germany) of a custom-made railing system (IonOptix, Milton, USA)
- 840 - Axial stretch applied by piezoelectric translators movement of carbon fibres, graded to cause
- 841 an increase in sarcomere length of $\sim 8\%$ in the stretched portion of the cell
- 842 - Sarcomere length changes confirmed via fast Fourier transformation of striation patterns in
- 843 confocal images

844 b) Whole-Cell Stretch:

- 845 - Carbon fibres attached to each cell end
- 846 - Ca^{2+} spark rate compared during 5-second intervals, before application of stretch,
- 847 immediately after onset of stretch, and at end of 1 minute of stretch

848 c) Half-Cell Stretch:

- 849 - One carbon fibre attached to centre of cell and other attached to one end of same cell
- 850 - Central carbon fibre remained stationary, with end-standing carbon fibre used to apply stretch
- 851 to half of cell, leaving remainder of cell relatively undisturbed
- 852 - Ca^{2+} sparks counted in both stretched and the non-stretched portion of cell, for 5 seconds,
- 853 immediately before and after application of stretch, and percentage change in Ca^{2+} spark rate
- 854 ("during stretch" divided by "pre-stretch" times 100) assessed separately for each cell half

855 d) Ca^{2+} Spark Measurements:

- 856 - Cells loaded with Fluo-4 by 10 minutes of incubation
- 857 - Excitation with 488 nm argon ion laser beam
- 858 - Emitted fluorescence detected above 505 nm
- 859 - XY confocal time series images acquired every 20 to 30 ms

860 e) Electron Microscopy and Tomography:

- 861 - Adult rat ventricular cardiomyocytes fixed for 40 minutes and post-fixed for 10 minutes
- 862 - Fixed cells dehydrated in acetone and embedded in Epon-Araldite resin (Electron Microscopy
- 863 Sciences, Hatfield, USA)
- 864 - Sections (250 nm) cut and transferred onto electron tomography grids

865 - Colloidal gold particles (15 nm) added to both surfaces of sections as fiducial markers

866 - Electron tomograms of preparations acquired

867 4. Recordings

868 4.1 Time window of recording

869 - As soon as possible after preparation, up to 6 hours

870 4.2 Spatial location of recording

871 - Entire cell area

872 4.4 Optical Measurements

873 4.4.1 Equipment (optical mapping system / microscope / light sources / filters / lenses / lens
874 numerical aperture / etc.)

875 - LSM 510 confocal microscope (Carl Zeiss MicroImaging GmbH, Jena, Germany) for XY
876 time series image acquisition

877 - LSM 5-Live microscope (Carl Zeiss MicroImaging GmbH, Jena, Germany) for fast XY time
878 series image acquisition

879 - Tecnai TF30 microscope (FEI Company, Eindhoven, The Netherlands), with images
880 captured on an Ultrascan 4K CCD camera (GATAN Inc, Pleasanton, USA), for electron
881 tomography image acquisition

882 4.4.2 Settings (pinhole / gain / offset / spatial and temporal sampling / scan modes / etc.)

883 - LSM 5-Live microscope: 512x30 pixel frame captured every 1.5 to 2.5 ms during half-cell
884 stretch protocol

885 - Tecnai TF30 microscope: At 300 kV

886 - Ultrascan 4K CCD camera: Nominal magnification of $\times 23,000$, projected image dimension of
887 $1.02 \times 1.02 \text{ nm}^2/\text{pixel}$, physical Nyquist XY resolution of 2.04 nm, physical Z resolution
888 affected by highest possible tilt angle α (α_{\max}) and cannot exceed $[\text{XY resolution}] \times$
889 $[\sin(\alpha_{\max})]^{-1}$, effective resolution $\sim 4\text{-}5 \text{ nm}$

890 4.8 Software environment (operating system / acquisition program version / supplier / etc.)

891 - LSM confocal microscope XY time series image acquisition: Operating system: Windows XP /
892 Acquisition program: Unavailable

893 - Tecnai microscope and Ultrascan camera tomography image acquisition: Operating system:
894 Unavailable / IMOD software (SerialEM, version Unavailable, available from the Boulder
895 Laboratory for 3-D Electron Microscopy of Cells; <http://bio3d.colorado.edu/imod/>)

896 5. Analysis

897 5.1 Software environment (operating system / program version/supplier / etc.)

898 - Custom routines for Ca^{2+} spark measurements written in Interactive Data Language version 6.2
899 (available from Christopher W. Ward; ward@son.umaryland.edu) and in Delphi (by Alan Garny;
900 alan.garny@dpag.ox.ac.uk)

901 - IMOD software for electron tomogram generation (eTOMO) and to generate 3D models of
902 relevant structures (3dmod) (version Unavailable, available from the Boulder Laboratory for 3-D
903 Electron Microscopy of Cells; <http://bio3d.colorado.edu/imod/>)

904 - GraphPad Prism 4 for statistical analysis (GraphPad Software, La Jolla, USA)

- 905 5.2 n number(s) (number of preparations/observations / number of preparations/observations per
906 subject / *etc.*)
- 907 - Unavailable
- 908 5.3 Observations inclusion/exclusion criteria / number of rejected observations
- 909 - Carbon fibre detachment
- 910 - Mechanical induction of Ca^{2+} waves
- 911 - Absence of background Ca^{2+} sparks
- 912 5.4 Signal-to-noise (method of calculation / *etc.*)
- 913 - Unavailable
- 914 5.5 Software based data processing (filtering / smoothing / binning / averaging / background signal
915 removal / normalisation / interpolation / extrapolation / deconvolution / *etc.*)
- 916 a) Ca^{2+} Spark Measurements:
- 917 - Five-frame running average applied for each time point of XY time series
- 918 - 4x4 boxcar filter applied to each image
- 919 - Area containing cardiomyocyte identified as region with intensity 1.5 standard deviations
920 greater than the background fluorescence
- 921 - Potential spark locations identified as contiguous pixel regions with intensity 2 standard
922 deviations greater than the cardiomyocyte mean intensity
- 923 - ΔF representation of each image constructed as local fluorescence intensity minus net
924 fluorescence in cardiomyocyte area outside potential spark locations
- 925 - Ca^{2+} sparks confirmed as contiguous pixel regions with intensity 3.8 standard deviations
926 greater than the cardiomyocyte mean intensity outside potential spark locations
- 927 - Ca^{2+} spark rate was calculated by analyzing Ca^{2+} spark frequency, with duplicate spark counts
928 at any coordinate (those that lasted throughout more than one of the contiguous frames)
929 subtracted
- 930 - XY regions from fast XY time series images containing individual sparks collapsed onto x-axis
931 to provide 1D signal intensity line (pseudo line-scan image)
- 932 - All 1D pseudo line-scan traces stacked in chronological order to create 2D X time sequence
933 (pseudo line-scan time plot)
- 934 - Time course of signal at centre line used to analyze spark amplitude, time to peak, and decay
935 time constant of the spark
- 936 b) Electron Microscopy and Tomography:
- 937 - Images from each electron tomography tilt-series aligned (by fiducial marker tracking) and
938 back-projected to generate 2 single full-thickness reconstructed volumes (tomograms), which
939 were combined to generate single high-resolution 3D reconstruction of original partial cell
940 volume
- 941 - Microtubules modelled as tubes with diameter of 24 nm and sarcoplasmic reticulum and T-
942 tubular membranes modelled by contours along the bilayer projection delimiting distinct
943 compartments, manually traced for each tomographic slice

- 944 - Model was smoothed (details Unavailable) and meshed (details Unavailable) to obtain final
945 3D representation, where spatial relationships among microtubules, sarcoplasmic reticulum,
946 and T-tubules were analyzed
- 947 5.6 Calculated parameters (QT-interval / QRS duration / endocardial activation / conduction
948 velocity / action potential duration to specified level of repolarisation / peak current / etc.)
- 949 - Sarcomere length (measured *via* fast Fourier transformation of striation patterns in confocal
950 images) / time to Ca²⁺ peak / spark amplitude ($\Delta F/F_o$) / decay time constant / spark rate
- 951 5.7 Sufficiently detailed description of statistical methods for offsite reproduction
- 952 - Paired Student's *t*-test and 2-way ANOVA (where appropriate) with a probability value of less
953 than 0.05 considered to indicate significant difference between means
- 954 5.8 Example(s) of raw and processed data (from the same recording)
- 955 - Will be provided in the online repository, once established, at <http://www.micee.org/>